Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive，HER2-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Early research (Phase 1)Looking for participantsNCT07604571
What this trial is testing

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Who this might be right for
Advanced HR+/HER2- Breast Cancer
Novartis Pharmaceuticals 194
Large-scale testing (Phase 3)Active Not RecruitingNCT03701334
What this trial is testing

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 5,101
Testing effectiveness (Phase 2)UnknownNCT06470672
What this trial is testing

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Fudan University 32
Testing effectiveness (Phase 2)UnknownNCT05800756
What this trial is testing

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

Who this might be right for
Breast Cancer
Yantai Yuhuangding Hospital 30
Large-scale testing (Phase 3)Active Not RecruitingNCT05365178
What this trial is testing

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Who this might be right for
HR-positive, HER2-negative Breast Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 432
Large-scale testing (Phase 3)Not Yet RecruitingNCT06996093
What this trial is testing

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
Fudan University 2,508
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Testing effectiveness (Phase 2)Looking for participantsNCT07258108
What this trial is testing

Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Sun Yat-sen University 35
Large-scale testing (Phase 3)Study completedNCT02600923
What this trial is testing

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

Who this might be right for
Advanced Breast Cancer Female
Pfizer 131
Testing effectiveness (Phase 2)Study completedNCT02344550
What this trial is testing

Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Asan Medical Center 137
Testing effectiveness (Phase 2)Looking for participantsNCT05524584
What this trial is testing

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHormone Receptor-positive Breast Cancer+1 more
University of California, Irvine 20
Not applicableStudy completedNCT05153187
What this trial is testing

Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan

Who this might be right for
Breast Cancer
Pfizer 1,170
Not applicableLooking for participantsNCT05878314
What this trial is testing

Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
University Hospital Tuebingen 504
Large-scale testing (Phase 3)Active Not RecruitingNCT04895358
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 342
Early research (Phase 1)Active Not RecruitingNCT06257264
What this trial is testing

Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Who this might be right for
Breast CancerSmall Cell Lung CancerOvarian Cancer+9 more
BeiGene 103
Large-scale testing (Phase 3)Study completedNCT02692755
What this trial is testing

Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Georgetown University 35
Testing effectiveness (Phase 2)Study completedNCT04836520
What this trial is testing

SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 20
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Next Page